NBDF/LinkedIn
Sep 11, 2025, 13:37
Marstacimab Shows 93% Reduction in Treated Bleeds in its Phase 3 Trial
National Bleeding Disorders Foundation shared on LinkedIn:
”Promising news for the hemophilia community!
Pfizer’s HYMPAVZI™ (marstacimab-hncq) shows a 93% reduction in treated bleeds in its Phase 3 trial for people with hemophilia A or B with inhibitors.”
Learn more here.
Stay updated on the emerging in the field of hemophilia with Hemostasis Today.
-
Feb 18, 2026, 16:47Sophia Delicou: Importance of Assessing Hemoglobin Functional Capacity Rather Than Total Levels
-
Feb 18, 2026, 16:32Cheng-Hock Toh: 5 Steps to Transform Transfusion Practice
-
Feb 18, 2026, 16:26Tareq Abadl: CMV and Transfusion – Leukoreduction vs CMV-Seronegative
-
Feb 18, 2026, 16:24Soroush Sohrabi: The Hidden Biology of Sclerotherapy and Mechanisms Beyond Endothelial Injury
-
Feb 18, 2026, 16:23Hamad Abbasi: Why are Coronary Stents so Expensive?
-
Feb 18, 2026, 16:08Carlos Doti: AstraZeneca’s Expanding Impact in Blood Cancer Care
-
Feb 18, 2026, 16:05Shiny K. Kajal: Routine vs Massive Transfusion Protocol
-
Feb 18, 2026, 16:03Maria Farid: Successful Consultative Hematology and Transfusion Medicine Workshop at PKLI
-
Feb 18, 2026, 15:59Ella Lawson: Could Erythritol Harm the Brain’s Blood Vessels?